中文摘要：

目的观察BVT．2733和吡格列酮（PGZ）对肥胖小鼠干预结果的异同，探讨BVT．2733在改善胰岛素抵抗中的作用机制。方法构建高脂饮食诱导的肥胖小鼠模型，分为正常对照组、肥胖对照组、BVT．2733治疗组、PGZ治疗组，对照组给予安慰剂，治疗组分别给予BVT．2733、PGZ灌胃2周，放免法检测小鼠空腹胰岛素水平，生化法检测血糖，ELISA法检测血清脂联素含量，实时定量PCR检测脂肪组织脂联素和瘦素的mRNA表达。观察4组小鼠在胰岛素抵抗方面的差异。结果与正常对照组相比，肥胖对照组小鼠脂肪细胞明显增大，体重增加，空腹血糖、血清胰岛素水平升高（P〈0．05）。与肥胖对照组比较，BVT．2733、PGZ治疗组鼠脂肪细胞体积减小，空腹血清胰岛素明显下降（P〈0．01）；PGZ组血清脂联素含量升高、脂肪组织脂联素和瘦素表达明显上调（P〈0．05）。BVT．2733治疗组小鼠体重明显减轻，而血清脂联素含量、脂肪组织脂联素和瘦素表达变化无统计学意义。结论BVT．2733能够显著减轻体重，改善胰岛素抵抗，但其不能影响脂肪细胞的分泌功能。

英文摘要：

Objective To investigate the mechanism of BVT. 2733 on insulin resistance, by using diet-induced obese （DIO） mice model. Methods After having been balanced for 3 days, the C57BL/6J mice were randomly divided into a normal diet group and a high-fat diet （HFD） group. After 20 weeks, the obese mice were further randomly divided into an obese control group, a BVT. 2733 group and a pioglitazone （PGZ） group and they were orally administered with placebo, BVT. 2733 and PGZ separately for two weeks. Adiponectin and leptin mRNA expression levels from adipose tissue were analyzed with real-time quantitative PCR. The levels of plasma glucose, serum insulin and adiponectin were measured with biochemical technology, radioimmunoassay and ELISA. Adipocyte sizes were observed with immunohistochemistry. Results The body weight, plasma glucose and serum insulin levels raised （P 〈 0. 05 ）in the HFD group and the adipocyte sizes were bigger. Serum insulin levels significantly reduced （ P 〈 0. 05 ） and adipocyte sizes reduced, while plasma adiponectin level raised （P 〈 0. 01 ）in the two treatment groups as compared with those in obese controls. Both the mRNA expressions of adiponectin and leptin upregnlated（P 〈0. 05）in the PGZ group, but their expressions in the BVT. 2733 group did not alter significantly. The body weight of the mice reduced significantly in the BVT. 2733 group. Conclusion BVT. 2733 can reduce body weight significantly and improve insulin resistance, but cannot influence the expression of adipocytokines.